Legal Troubles At Hemispherx
Now that we finally started to see some light at the end of the New Drug Application (NDA) tunnel for Hemispherx Biopharma (HEB – $1.00) , they seem to have sailed into murky legal waters. Since its November 2 press release, in which the Company gave an update on its NDA for Ampligen, several law firms have filed a class […]
Read more